TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest update is out from Ocumension Therapeutics ( (HK:1477) ).
Ocumension Therapeutics has announced a board meeting scheduled for August 21, 2025, to review and approve the company’s interim results for the first half of the year and discuss the potential recommendation of an interim dividend. This meeting is significant for stakeholders as it will provide insights into the company’s financial health and strategic decisions moving forward.
The most recent analyst rating on (HK:1477) stock is a Hold with a HK$9.78 price target. To see the full list of analyst forecasts on Ocumension Therapeutics stock, see the HK:1477 Stock Forecast page.
More about Ocumension Therapeutics
Ocumension Therapeutics is a company incorporated in the Cayman Islands, focusing on the pharmaceutical industry. It specializes in developing and commercializing ophthalmic therapies, targeting eye-related diseases and conditions.
Average Trading Volume: 8,829,500
Technical Sentiment Signal: Buy
Current Market Cap: HK$8.68B
For detailed information about 1477 stock, go to TipRanks’ Stock Analysis page.